Drug Trial Radar · NCT06590324
A Study of Apabetalone in Subjects With Long -COVID
Last checked: Nov 19, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Dec 30, 2025
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Resverlogix CorpIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.
Conditions
- Post-Acute COVID-19 Syndrome
Interventions
ApabetaloneDrug
100-mg capsule, twice daily oral administration with meals
Primary outcomes
What the sponsor says the trial is designed to measure.
- patient acceptable symptom state (PASS)Time frame: 90 days
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
The Speciality Hospital
Amman, Jordan · Not yet recruiting
MNGHA- King Abdulaziz Hospital
Al Mubarraz, Saudi Arabia · Not yet recruiting
Al Kuwait Hospital
Dubai, Dubai, United Arab Emirates · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.